Triple-negative breast cancer is one of the most aggressive forms of the disease and is often diagnosed at a later stage. Options for treatment of the disease are limited, but a new clinical trial is showing promising outcomes.
This study finds that women with triple-negative breast cancer lived longer if they received a combination of immunotherapy and chemotherapy compared with chemotherapy alone. These results are expected to be practice changing for other people diagnosed with the disease.
Sylvia Adams, MD, a director of clinical research at NYU Langone’s Perlmutter Cancer Center and associate professor of medicine in the Division of Hematology and Medical Oncology, spoke with The New York Times about the groundbreaking clinical trial that she led in the United States. “This is truly a game changer,” she says.
Read more from The New York Times.